FDAnews
www.fdanews.com/articles/73549-first-enrollment-complete-for-taxus-liberte-registry

FIRST ENROLLMENT COMPLETE FOR TAXUS LIBERTE REGISTRY

June 22, 2005

Boston Scientific has completed enrollment in the transitional phase of what the company claims will be the world's largest drug-eluting stent registry.

The Olympia registry plans to enroll more than 30,000 patients at more than 600 centers in the U.S., Europe and other international locations. The registry is designed to collect and analyze "real-world" clinical outcomes data for Boston Scientific's next-generation Taxus Liberte paclitaxel-eluting stent system in the treatment of patients with coronary artery disease in markets where the product is commercially available.